Skip to content

Efficacy of Hridayarnava Rasa on hyperlipidemia

Pharmaco-therapeutic efficacy of Hridayarnava Rasa prepared with two different methods of Tamra Amritikarana on hyperlipidemia - HRTBA

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/08/006127
Enrollment
60
Registered
2015-08-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Hyperlipidemia

Interventions

Intervention1: Hridayarnava Rasa prepared with using Tamra Bhasma from Surana method of Amritikarana: 125mg with honey twice a day for 8 weeks with 2 weeks follow up Control Intervention1: Hridayarnav

Sponsors

Institute for Post Graduate Teaching and Research in Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age between 20 to 60 years Elevated levels of S. Cholesterol ( >200mg/dL) and/or Elevated S. Triglycerides ( >150mg/dL) and/or Elevated S.LDL ( >130mg/dL) and/or Elevated S. VLDL ( >40mg/dL)

Exclusion criteria

Exclusion criteria: Age less than 20 years and more than 60 years. Any concomitant serious disorders of liver, kidneys, heart, lung and other organs. Gravid women and lactating mothers. Persons undergoing treatment for any other serious illness.

Design outcomes

Primary

MeasureTime frame
It is expected that the trial drugs will exert a significant action over lipids of different categories (cholesterol, triglyceride, LDL, VLDL, HDL)Timepoint: up to 8 weeks

Secondary

MeasureTime frame
By maintaining the healthy level of lipids, the drug will control conditions associated with hyperlipidemia like various cardiovascular diseases such as Atherosclerosis, Cardiac Arrest, Stroke, Heart Attack, etc.Timepoint: up to 8 weeks

Countries

India

Contacts

Public ContactDr Galib

I P G T and R A GAU Jamnagar

galib14@yahoo.co.in9428671275

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026